At the end of February, in Tashkent, a trilateral agreement was signed on the implementation of an investment project for the construction of a plant for the production of medicines in the Bostanlyk district of the Tashkent region, worth over $ 20 million. The annual production capacity is expected to be 500 million tablets, 200 million capsules and 10 million sachets (powders). The production of more than 120 types of drugs is planned.
On behalf of the Uzbek side, the agreement was signed by the deputy khokim of the Tashkent region Jamshid Abdusalomov and the director of the Agency for the Development of the Pharmaceutical Industry Sardor Kariev.
Executive Director of “Solyphar” Omar Abd al-Alim, who signed the agreement on behalf of the Egyptian side, spoke in an interview about the details of this project, and in general about the experience and prospects of cooperation with Uzbekistan.
The company “Solyphar” is one of the leading players in the pharmaceutical market in Egypt, also carries out active international cooperation. In particular, we have many years of experience in the CIS countries, including Azerbaijan, Kazakhstan and other countries.
The company’s cooperation with Uzbekistan began in 2011 with the export of pharmaceutical products. In 2019, the company began to consider the possibility of investing in this industry.An important motive for expanding cooperation with Uzbekistan was the open economic and investment policy pursued in the republic under the leadership of President Shavkat Mirziyoyev. It was noted that over the past four years, the country has undergone radical changes in attracting foreign investment, ensuring currency convertibility, and providing guarantees for foreign investors.
In 2018, a very important visit to Uzbekistan of an Egyptian government delegation, consisting of representatives of the ministries of foreign affairs, agriculture, health, as well as the business circles of Egypt, took place. During the visit, Solyphar signed a memorandum of cooperation with the Agency for the Development of the Pharmaceutical Industry under the Ministry of Health of Uzbekistan.
The project provides for the construction of a pharmaceutical plant on the territory of the free economic zone located in the Bostanlyk district of the Tashkent region. It was noted that a convenient location with the necessary infrastructure will reduce the cost of logistics and provision of resources.
The project in Uzbekistan is the first major project involving direct investment that Solyphar is implementing abroad. The new production will meet the requirements of Good Manufacturing Practice – GMP. To ensure a high level of product quality, “Solyphar” actively cooperates with the German company International Quality Consulting (IQC) Group.
Другие новости и события
Any use (reproduction, publication, copying, reprinting, distribution, translation, broadcasting, processing and other methods of distribution) of the materials of the Investment Portal - Invest.gov.uz, without indicating the original source and a link to the Portal is strictly prohibited!